Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 15;8:13. doi: 10.1038/s41421-021-00366-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Immunohistochemistry of ZNF667 shows variations of abundance across patients using the tissue microarray analysis. b Overall survival and progression-free survival of self-collected PDAC patients grouped by the abundance of ZNF667. c Relative abundance of ZNF667 and ZNF667-AS1 to ACTB mRNA in normal pancreas cells (HPDE6-C7), human embryonic kidney cells (HEK293T), liver metastasis pancreas cancer cells (L3.7), and the pancreas cancer cells detected by RT-qPCR. All pancreas cancer cells showed a decreased level of ZNF667 and ZNF667-AS1. *P < 0.05; **P < 0.01. d Immunoblot showing the decreased abundance of ZNF667 in multiple pancreas cancer cell lines. The abundance was calculated at the bottom. e, f Validation of ZNF667 and ZNF667-AS1 overexpression (OE) in two pancreas cancer cell lines. **P < 0.01; ****P < 0.0001. g Immunoblot showing the abundance of ZNF667 in PANC-1 and SW1990 cells before and after overexpression. h, i Proliferation evaluation (CCK8-positive cell ratio) after ZNF667 and ZNF667-AS1 overexpression in two pancreas cancer cell lines. n = 3 for each time point. **P < 0.001; ****P < 0.00001. j Evaluation of cellular apoptosis after ZNF667-AS1 overexpression in two pancreas cancer cell lines. n.s., no significance.